Tissue factor pathway inhibitor: Clinical deficiency states

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 467-470

  Sandset, Per Morten ^a   Bendz, Bjørn ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; PROTEINASE INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR;

AMINO TERMINAL SEQUENCE; ANTICOAGULATION; CARBOXY TERMINAL SEQUENCE; CONFERENCE PAPER; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SCREENING; VEIN THROMBOSIS;

EID: 0030793124     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657571     Document Type: Conference Paper

References (45)

1. Wun T-C, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA for coding for the lipoprotein associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263:6001-4.
2. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard, JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits factor Xa:Insight into its possible mechanism of action. Blood 1988; 71:335-43.
3. Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor:Evidence for a two-step model of inhibition. Thromb Haemost 1988; 60:452-6.
4. Callander NS, Rao LVM, Nordfang O, Sandset PM, Warn-Cramer B, Rapaport SI. Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. J Biol Chem 1992; 267:876-82.
5. Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 1985; 66:204-12.
6. Hubbard AR, Jennings CA. Inhibition of tissue thromboplastin-mediated blood coagulation. Thromb Res 1986; 42:489-98.
7. Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47:389-400.
8. Almus FE, Rao LVM, Rapaport SI. Functional properties of factor VIIa/tissue factor formed with purified tissue factor and with tissue factor expressed on cultured endothelial cells. Thromb Haemost 1989; 62:1067-73.
9. Gramzinski RA, Broze GJ, Carson SD. Human fibroblast tissue factor is inhibited by lipoprotein-associated coagulation inhibitor and placental anticoagulant protein but not by apolipoprotein A-II. Blood 1989; 73:983-9.
10. Lindhout T, Blezer R, Schoen P, Nordfang O, Reutelingsperger C, Hemker HC. Activation of factor X and its regulation by tissue factor pathway inhibitor in small diameter capillaries lined with human endothelial cells. Blood 1992; 79:2909-16.
11. Lindahl AK, Sandset PM, Thune-Wiiger M, Nordfang O, Sakariassen K. Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix. Blood Coagul Fibrinolysis 1994; 5:755-60.
12. Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze GJJr, Warren TG, Wun T-C. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990; 76:1538-45.
13. Bregengaard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coagul Fibrinolysis 1993; 4:699-706.
14. Creasy AA, Chang ACK, Feigen L, Wun T-C, Taylor FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-60.
15. Spokes EG, Wun T-C. Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis. JMP 1992; 27: 225-32.
16. 1-161) in experimental venous thrombosis - a comparison with low molecular weight heparin. Thromb Haemost 1994; 71:214-9.
17. Haskel EK, Torr SR, Day KC, Palmier MO, Wun T-C, Sobel BE, Abendschein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991; 84:821-7.
18. Lane DA, Olds RJ, Boisclair M, Chowdhury V, Thein SL, Cooper DN, Blajchman M, Perry D, Emmerich J, Aiach M. Antithrombin III mutation database: first update. Thromb Haemost 1993; 70:361-9.
19. Pabinger I, Allaart CF, Hermans J, Briet E, Bertina RM. Hereditary protein C-deficiency: laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC subcommittee on protein C and protein S. Thromb Haemost 1992; 68:470-4.
20. Dahlbäck B. The protein C anticoagulant system: Inherited defects as basis for venous thrombosis. Thromb Res 1995; 77:1-43.
21. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988, 50, 803-13.
22. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ. Plasma antigen levels of the lipoprotein associated coagulation inhibitor in patient samples. Blood 1991; 78, 387-93.
23. Hubbard AR, Weller LJ, Gray E. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coagul Fibrinolysis 1994; 5:819-23.
24. Hansen JB, Sandset PM, Huseby KR, Huseby N-E, Nordøy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous infusion of heparin in man. Thromb Haemost 1996; 76:703-9.
25. Hubbard AR, Jennings CA. Inhibition of tissue factor-factor VIIa complex: Involvement of factor Xa and lipoproteins. Thromb Res 1987; 46:527-37.
26. Warn-Cramer BJ, Maki SL, Zivelin A, Rapaport SI. Partial purification and characterization of extrinsic pathway inhibitor (the factor Xa dependet inhibitor of factor VIIa/tissue factor). Thromb Res 1987; 48:11-22.
27. Novotny WF, Girard JP, Miletich JP, Broze, GJJr. Purification and characterization of the lipoprotein associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264:18832-7.
28. Hansen J-B, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordøy A. Tissue factor pathway inhibitor and lipoproteins: Evidence for association with and regulation by LDL in human plasma. Arterioscl Thromb 1994; 14:223-9.
29. Novotny WF, Girard JP, Miletich JP, Broze GJ. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988; 72: 2020-5.
30. Sandset PM, Abildgaard U. Extrinsic pathway inhibitor - the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21:219-39.
31. Warr TA, Warn-Cramer BJ, Rao LVM, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay an evaluation of physiologic variables. Blood 1989; 74:201-6.
32. Wun T-C, Hyang MD, Kretzmer KK, Palmier MO, Day KC, Bulock JW, Folk KF, Broze GJ. Immunoaffinity purification and characterization of lipoprotein associated coagulation inhibitor from HepG2 hepatoma, Chang liver, and SK hepatoma cells. J Biol Chem 1990; 27:16096-101.
33. Lindahl AK, Abildgaard U, Larsen ML, Staalesen R, Hammer AKG, Sandset PM, Nordfang O, Beck T. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thromb Res 1991; 62:607-14.
34. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in postheparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis 1991; 2:713-21.
35. Kowaka T, Abumiya T, Kimura T, Harada-Shiba M, Koh H, Tsushima M, Yamamoto A, Kato H. Tissue factor pathway inhibitor activity in huma plasma. Measurment of lipoprotein-associated and free forms in hyperlipidemia. Arterioscl Thromb Vasc Biol 1995; 15:504-10.
36. Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscl Thromb 1991; 11:138-45.
37. Hansen J-B, Huseby KR, Huseby NE, Sandset PM, Hanssen T-A, Nordøy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscl Thromb Vasc Biol 1995; 15:879-85.
38. Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI. Immunodepletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88:708-12.
39. Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 1991; 78:1496-502.
40. Llobet D, Falkon L, Mateo J, Vallvé, Martinez E, Fontcuberta J, Borrell M. Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia. Thromb Res 1995; 80:413-8.
41. Goodwin CA, Melissari E, Kakkar VV, Scully MF. Plasma levels of tissue factor pathway inhibitor in thrombophilic patients. Thromb Res 1993; 71:363-6.
42. Bajaj MD, Rana SV, Wysolmerski RB, Bajaj SP. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79:1874-8.
43. Brandztzaeg P, Sandset PM, Joø GB, Øvstebø R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989; 55:459-70.
44. Warr TA, Rao LVM, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 1989; 74:994-8.
45. Lindahl AK, Abildgaard U, Stokke G. Extrinsic pathway inhibitor after heparin injection: Increased response in cancer patients. Thromb Res 1990; 59:651-6.